Drugs / 131-I-chTNT-1/B MAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00509301 | Nov 2006 → Mar 2010 | glioblastoma | Peregrine Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131-I-chTNT-1/B MAB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00509301 ↗ |
| Modality | Monoclonal antibody | “a targeted monoclonal antibody” NCT00509301 ↗ |
| Route | Other | “The study drug is given interstitially” NCT00509301 ↗ |